faricimab

Faricimab is indicated for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

The most common adverse reaction reported in people receiving faricimab include conjunctival bleeding.

Contraindications to injection of faricimab include active infection in or around the eye, active inflammation in the eye (uveitis), and prior allergic reactions to receiving the drug (hypersensitivity).

There are no adequate and well-controlled studies of faricimab administration in pregnant women.

There is no information regarding faricimab accumulation in breast milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. However, the drug company states that many drugs are transferred in human milk with the potential for absorption and adverse reactions in the breastfed child.

No studies on the effects of faricimab on human fertility have been conducted and it is not known whether faricimab can affect reproduction. Based on its mechanism of action, treatment with may pose a risk to reproductive capacity.

Faricimab is a 150kDa-sized bispecific antibody whose molecular structure allows a high affinity bond to both vascular endothelial growth factor A (VEGF-A) and Angiopoietin (Ang-2). By blocking the action of these two growth factors, faricimab decreases migration and replication of endothelial cells allowing for stabilization of vascular structures, thereby decreasing vascular leakage.{{cite journal | vauthors = Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM | title = Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab | journal = Cells | volume = 9 | issue = 8 | page = 1869 | date = August 2020 | pmid = 32785136 | pmc = 7464130 | doi = 10.3390/cells9081869 | doi-access = free }}{{cite journal | vauthors = Iglicki M, González DP, Loewenstein A, Zur D | title = Next-generation anti-VEGF agents for diabetic macular oedema | journal = Eye | volume = 36 | issue = 2 | pages = 273–277 | date = February 2022 | pmid = 34373607 | pmc = 8807622 | doi = 10.1038/s41433-021-01722-8 | url = http://dx.doi.org/10.1038/s41433-021-01722-8 | access-date = 30 July 2022 | url-status = live | archive-url = https://web.archive.org/web/20220730051400/https://www.nature.com/articles/s41433-021-01722-8 | archive-date = 30 July 2022 }}{{cite journal | vauthors = Fenner BJ, Cheung CM, Sim SS, Lee WK, Staurenghi G, Lai TY, Ruamviboonsuk P, Kokame G, Yanagi Y, Teo KY | display-authors = 6 | title = Evolving treatment paradigms for PCV | journal = Eye | volume = 36 | issue = 2 | pages = 257–265 | date = February 2022 | pmid = 34262165 | pmc = 8807588 | doi = 10.1038/s41433-021-01688-7 | url = http://dx.doi.org/10.1038/s41433-021-01688-7 | access-date = 30 July 2022 | url-status = live | archive-url = https://web.archive.org/web/20220730051402/https://www.nature.com/articles/s41433-021-01688-7 | archive-date = 30 July 2022 }} Faricimab has shown improved and sustained efficacy in comparison to agents that only target the VEGF pathway.

In 2016, pre-clinical studies looking at the mechanism of action behind faricimab showed that by blocking Ang-2, one of the drug's targets, there was decreased endothelial barrier breakdown in blood vessels. In 2017, phase I studies in neovascular age related macular degeneration (nAMD) showed that the drug was safe to use in people and well tolerated.

On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vabysmo, intended for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). The applicant for this medicinal product is Roche Registration GmbH.{{cite web | title=Vabysmo: Pending EC decision | website=European Medicines Agency | date=22 July 2022 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vabysmo | access-date=29 July 2022 | archive-date=28 July 2022 | archive-url=https://web.archive.org/web/20220728183712/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/vabysmo | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged. Faricimab was approved for medical use in the European Union in September 2022.{{cite web | title=Vabysmo EPAR | website=European Medicines Agency (EMA) | date=19 July 2022 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo | access-date=14 October 2022 | archive-date=14 October 2022 | archive-url=https://web.archive.org/web/20221014033224/https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo | url-status=live }}{{cite web | title=Vabysmo Product information | website=Union Register of medicinal products | url=https://ec.europa.eu/health/documents/community-register/html/h1683.htm | access-date=3 March 2023 | archive-date=27 October 2022 | archive-url=https://web.archive.org/web/20221027221237/https://ec.europa.eu/health/documents/community-register/html/h1683.htm | url-status=live }}

Faricimab is the International Nonproprietary Name (INN).{{cite journal | vauthors = ((World Health Organization)) | title = International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 80 | journal = WHO Drug Information | volume = 32 | issue = 3 | year = 2018 | hdl = 10665/330907 | hdl-access = free | author-link = World Health Organization }} Faricimab was formerly named RG7716.{{cite journal | vauthors = Kaplon H, Chenoweth A, Crescioli S, Reichert JM | title = Antibodies to watch in 2022 | journal = mAbs | volume = 14 | issue = 1 | pages = 2014296 | date = January 2022 | pmid = 35030985 | pmc = 8765076 | doi = 10.1080/19420862.2021.2014296 }}

Two phase II trials evaluated faricimab's efficacy and safety in comparison to ranibizumab and showed that faricimab received every 16 weeks and every twelve weeks was comparable to ranibizumab received every four weeks in visual acuity and imaging outcomes. In 2019, two phase III multi-center randomized studies TENAYA and LUCERNE were initiated on 1,200 participants with neovascular age related macular degeneration (nAMD) to evaluate faricimab's safety, efficacy, and durability against aflibercept. Both studies reached its primary endpoints and showed that faricimab given at up to every 16 weeks was non-inferior to aflibercept administered every 8 weeks. Faricimab demonstrated its potential to extend the time between intravitreal injections in nAMD patients.{{cite journal | vauthors = Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CM, Wong TY | display-authors = 6 | title = Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials | journal = Lancet | volume = 399 | issue = 10326 | pages = 729–740 | date = February 2022 | pmid = 35085502 | doi = 10.1016/s0140-6736(22)00010-1 | s2cid = 246242760 | url = https://publicatio.bibl.u-szeged.hu/24214/1/TheLancet729-740.pdf | access-date = 10 March 2024 | archive-date = 31 May 2023 | archive-url = https://web.archive.org/web/20230531004258/http://publicatio.bibl.u-szeged.hu/24214/1/TheLancet729-740.pdf | url-status = live }}

One phase II trial evaluated faricimab's efficacy and safety in comparison to ranibizumab and showed clinically meaningful and statistically significant improvements in visual acuity.{{Cite press release|title=Phase II data support potential for Roche's novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema|url=https://www.roche.com/investors/updates/inv-update-2018-02-12.htm|access-date=17 February 2022|website=Roche|archive-date=17 February 2022|archive-url=https://web.archive.org/web/20220217170415/https://www.roche.com/investors/updates/inv-update-2018-02-12.htm|url-status=live}} Two phase III multi-center randomized studies were completed on 1,891 diabetic participants with diabetic macular edema (DME).{{cite journal | vauthors = Sharma A, Kumar N, Parachuri N, Karanam D, Kuppermann BD, Bandello F, Regillo CD | title = Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials | journal = Eye | volume = 36 | issue = 4 | pages = 679–680 | date = April 2022 | pmid = 34718339 | pmc = 8956679 | doi = 10.1038/s41433-021-01831-4 | s2cid = 240157515 }}

In two phase III trials, faricimab met the primary endpoint of non-inferior visual acuity gains when compared with aflibercept in 553 participants with macular edema due to branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) in the BALATON and COMINO studies.{{ClinicalTrialsGov|NCT04740905|A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)}}{{ClinicalTrialsGov|NCT04740931|A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)}}{{Cite web |title=Roche touts positive top-line Phase III results for Vabysmo |url=https://www.thepharmaletter.com/article/roche-touts-positive-top-line-phase-iii-results-for-vabysmo |access-date=28 October 2022 |website=The Pharma Letter |archive-date=28 October 2022 |archive-url=https://web.archive.org/web/20221028110530/https://www.thepharmaletter.com/article/roche-touts-positive-top-line-phase-iii-results-for-vabysmo |url-status=live }}

{{Reflist}}

• {{ClinicalTrialsGov|NCT03622580|A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)}}
• {{ClinicalTrialsGov|NCT03622593|A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)}}
• {{ClinicalTrialsGov|NCT03823287|A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)}}
• {{ClinicalTrialsGov|NCT03823300|A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)}}

{{monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}

{{Ocular vascular disorder agents}}

{{Growth factor receptor modulators}}

{{Portal bar | Medicine}}

Category:Angiogenesis inhibitors

Category:Drugs developed by Genentech

Category:Drugs developed by Hoffmann-La Roche

Category:Monoclonal antibodies

Category:Ophthalmology drugs